What is the main purpose of this 8-K filing?

This 8-K filing primarily announces material definitive agreements and actions related to executive compensation. It details clarifications to the 2006 Performance Incentive Plan and discloses salary adjustments and long-term incentive awards for key executive officers following promotions and expanded roles.

How will the Guidant acquisition impact the performance incentive plan?

The company has clarified that for the 2006 Performance Incentive Plan, the achievement of quality, sales, and profitability goals will be determined separately for the legacy Boston Scientific operations and the legacy Guidant Corporation operations. This ensures that performance is evaluated within the context of each entity before full integration.

What types of long-term incentive awards were granted to executives?

The long-term incentive awards granted to executives consist of two components: (i) stock options to purchase common stock at fair market value, vesting over four years, and (ii) deferred stock units (DSUs), also vesting over four years, to be issued annually starting on the second anniversary of the grant date.

Which executives received new roles or compensation adjustments?

The filing specifically mentions salary increases and long-term incentive awards for Brian Burns (Senior Vice President, Quality), Jeffrey Goodman (Executive Vice President, International), William Kucheman (Senior Vice President and Group President, Interventional Cardiology), and Ken Pucel (Executive Vice President, Operations). William Kucheman was also appointed to the Executive Committee.

BSX 8-K: Material Agreements

Summary

Boston Scientific Corporation (BSX) filed an 8-K on November 6, 2006, reporting on actions taken by its Board of Directors and committees on October 31, 2006. The primary focus of this filing is the clarification of the 2006 Performance Incentive Plan and the compensation adjustments for several executive officers following promotions and expanded responsibilities. Notably, the company will assess performance goals for the legacy Boston Scientific and legacy Guidant Corporation entities separately for incentive plan purposes, a significant detail given the recent acquisition of Guidant. In addition to the incentive plan clarification, the filing details salary increases and long-term incentive awards for key executives. These awards include stock options and deferred stock units (DSUs), designed to align executive compensation with company performance and long-term value creation. The report provides specific details on new base salaries, performance incentive plan opportunities, and the structure of the long-term awards for named individuals. Investors should note the emphasis on quality, sales, and profitability metrics, alongside the strategic integration implications of the Guidant acquisition.

Key Highlights

1Clarification of the 2006 Performance Incentive Plan to measure quality, sales, and profitability goals separately for legacy Boston Scientific and legacy Guidant Corporation.
2Approval of promotions and expanded job responsibilities for certain executive officers.
3Appointment of William Kucheman to the Company's Executive Committee.
4Salary increases for executive officers receiving expanded responsibilities.
5Approval of long-term incentive awards, including stock options and deferred stock units (DSUs), under the 2003 Long-Term Incentive Plan.
6Specific details provided on new base salaries and performance incentive plan opportunities for Brian Burns, Jeffrey Goodman, William Kucheman, and Ken Pucel.
7Stock options and DSUs vest over several years, beginning one and two years after the grant date, respectively.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (Nov 6, 2006)

Summary

Key Highlights

Frequently Asked Questions